Compounds > propylene glycol methyl ether acetate
Page last updated: 2024-12-05

propylene glycol methyl ether acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Propylene glycol methyl ether acetate (PGMEA) is a colorless, volatile liquid with a sweet odor. It is a widely used solvent in the electronics industry, particularly in the manufacture of semiconductors and flat-panel displays. PGMEA is also used as a solvent in various other applications, including paints, coatings, adhesives, and inks. PGMEA is synthesized by the reaction of propylene glycol methyl ether with acetic acid. The reaction is typically catalyzed by an acid catalyst, such as sulfuric acid. The effects of PGMEA on human health are of concern, as it is known to be a skin and eye irritant. It is also flammable and can be harmful if inhaled. PGMEA is studied because of its importance in the electronics industry and other applications. Research is ongoing to evaluate its potential environmental and health effects. '

propylene glycol methyl ether acetate: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7946
CHEMBL ID3182130
SCHEMBL ID15667
MeSH IDM0487319

Synonyms (62)

Synonym
ai3-18548
dowanol (r) pma glycol ether acetate
nsc 2207
1-methoxy-2-propanol acetate
propylene glycol monomethyl ether acetate
propyleneglycol monomethyl ether acetate
einecs 203-603-9
1-methoxy-2-acetoxypropane
brn 1751656
AKOS015837930
nsc-2207
108-65-6
2-acetoxy-1-methoxypropane
nsc2207
2-propanol, acetate
acetic acid, 2-methoxy-1-methylethyl ester
2-methoxy-1-methylethyl acetate
2-propanol, 1-methoxy-, acetate
1-methoxy-2-propyl acetate
propylene glycol methyl ether acetate
propylene glycol monomethyl ether acetate, reagentplus(r), >=99.5%
propylene glycol monomethyl ether acetate, >=99.0% (gc)
propylene glycol monomethyl ether acetate, 99%
1-methoxypropan-2-yl acetate
inchi=1/c6h12o3/c1-5(4-8-3)9-6(2)7/h5h,4h2,1-3h3
llhkcfnblrbogn-uhfffaoysa-
P1171
propylene glycol 1-monomethyl ether 2-acetate
1,2-propanediol 1-monomethyl ether 2-acetate
NCGC00249046-01
cas-108-65-6
NCGC00258987-01
dtxsid1026796 ,
tox21_201436
dtxcid106796
FT-0675939
pa7o2u6s2q ,
ec 203-603-9
2-propanol, 1-methoxy-, 2-acetate
unii-pa7o2u6s2q
hsdb 8443
methoxyisopropyl acetate
SCHEMBL15667
J-504836
propyleneglycolmethyletheracetate
propylene glycol monomethylether acetate
propyleneglycol methyl ether acetate
1-methoxy-2-acetoxy propane
propylene glycol 1-methyl ether 2-acetate
dowanol pma
arcosolv pma
ektasolve pm acetate
2-(1-methoxy)propyl acetate
CHEMBL3182130
su 8 developer
methoxyisopropyl acetate [inci]
1,2-propanediol monomethyl ether acetate
mfcd00038500
propylene glycol monomethyl ether acetate, vetec(tm) reagent grade
Q2170375
propylene glycol 1-methyl ether 2-acetate 100 microg/ml in acetonitrile
EN300-1725866

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The no observed adverse effect level (NOAEL) for 13-week inhalation exposures to Methoxyisopropanol was 1000 ppm in rats and rabbits."( Final report on the safety assessment of methoxyisopropanol and methoxyisopropyl acetate as used in cosmetics.
, 2008)		0.35

Pharmacokinetics

ExcerptReferenceRelevance
" The dose-response relationship for sedation was characterized using internal dose measures as predicted by a physiologically-based pharmacokinetic (PBPK) model for PGME and its acetate."( Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether
Corley, R; Gargas, ML; Kirman, CR; Sweeney, LM, 2005)		0.33

Dosage Studied

ExcerptRelevanceReference
" The dose-response relationship for sedation was characterized using internal dose measures as predicted by a physiologically-based pharmacokinetic (PBPK) model for PGME and its acetate."( Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether
Corley, R; Gargas, ML; Kirman, CR; Sweeney, LM, 2005)		0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency21.51360.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency2.61960.000221.22318,912.5098AID743053
progesterone receptorHomo sapiens (human)Potency0.96100.000417.946075.1148AID1346795
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency76.33310.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.63940.000229.305416,493.5996AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency42.92530.000723.06741,258.9301AID743122
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.08400.000627.21521,122.0200AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.28 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index80.15 (26.88)
Search Engine Supply Index2.75 (0.95)

This Compound (42.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
propylene glycol methyl ether
propylene glycol methyl ether: RN given refers to unspecified methoxypropanol; structure		2.9740
ozone
Ozone: The unstable triatomic form of oxygen, O3. It is a powerful oxidant that is produced for various chemical and industrial uses. Its production is also catalyzed in the ATMOSPHERE by ULTRAVIOLET RAY irradiation of oxygen or other ozone precursors such as VOLATILE ORGANIC COMPOUNDS and NITROGEN OXIDES. About 90% of the ozone in the atmosphere exists in the stratosphere (STRATOSPHERIC OZONE).. ozone : An elemental molecule with formula O3. An explosive, pale blue gas (b.p. -112degreeC) that has a characteristic, pungent odour, it is continuously produced in the upper atmosphere by the action of solar ultraviolet radiation on atmospheric oxygen. It is an antimicrobial agent used in the production of bottled water, as well as in the treatment of meat, poultry and other foodstuffs.		2.0310elemental molecule;
gas molecular entity;
reactive oxygen species;
triatomic oxygen		antiseptic drug;
disinfectant;
electrophilic reagent;
greenhouse gas;
mutagen;
oxidising agent;
tracer
albiflorin
albiflorin: glucoside in peony roots. albiflorin : A monoterpene glycoside with formula C23H28O11, originally isolated from the roots of Paeonia lactiflora.		2.2110benzoate ester;
beta-D-glucoside;
bridged compound;
gamma-lactone;
monoterpene glycoside;
secondary alcohol		neuroprotective agent;
plant metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Atherogenesis
[description not available]		02.2110
Leukemia, Acute Monocytic
[description not available]		02.2110
Leukemia, Monocytic, Acute
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.		02.2110
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.2110
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.0210